These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 20967296)

  • 1. Eribulin mesilate, a halichondrin B analogue, in the treatment of breast cancer.
    Mani S; Swami U
    Drugs Today (Barc); 2010 Sep; 46(9):641-53. PubMed ID: 20967296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eribulin mesylate.
    Jain S; Vahdat LT
    Clin Cancer Res; 2011 Nov; 17(21):6615-22. PubMed ID: 21859830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eribulin mesylate: a novel halichondrin B analogue for the treatment of metastatic breast cancer.
    McBride A; Butler SK
    Am J Health Syst Pharm; 2012 May; 69(9):745-55. PubMed ID: 22517020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eribulin mesylate: a promising new antineoplastic agent for locally advanced or metastatic breast cancer.
    Cortes J; Lorca R
    Future Oncol; 2011 Mar; 7(3):355-64. PubMed ID: 21375468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eribulin mesylate (E7389): review of efficacy and tolerability in breast, pancreatic, head and neck, and non-small cell lung cancer.
    Scarpace SL
    Clin Ther; 2012 Jul; 34(7):1467-73. PubMed ID: 22739019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eribulin mesylate in the management of metastatic breast cancer and other solid cancers: a drug review.
    Polastro L; Aftimos PG; Awada A
    Expert Rev Anticancer Ther; 2014 Jun; 14(6):649-65. PubMed ID: 24852360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eribulin mesylate for the treatment of breast cancer.
    Cigler T; Vahdat LT
    Expert Opin Pharmacother; 2010 Jun; 11(9):1587-93. PubMed ID: 20450446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eribulin -- a review of preclinical and clinical studies.
    Swami U; Chaudhary I; Ghalib MH; Goel S
    Crit Rev Oncol Hematol; 2012 Feb; 81(2):163-84. PubMed ID: 21493087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and safety of eribulin mesylate: a new therapeutic option in the treatment of metastatic breast cancer.
    O'Sullivan Coyne G; Walsh J; Kelly CM
    Expert Opin Drug Saf; 2012 Jul; 11(4):643-50. PubMed ID: 22694309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eribulin mesylate.
    Huyck TK; Gradishar W; Manuguid F; Kirkpatrick P
    Nat Rev Drug Discov; 2011 Mar; 10(3):173-4. PubMed ID: 21358731
    [No Abstract]   [Full Text] [Related]  

  • 11. Eribulin, a simplified ketone analog of the tubulin inhibitor halichondrin B, for the potential treatment of cancer.
    Newman S
    Curr Opin Investig Drugs; 2007 Dec; 8(12):1057-66. PubMed ID: 18058576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eribulin therapy for the treatment of patients with advanced soft tissue sarcoma.
    Seetharam M; Kolla KR; Chawla SP
    Future Oncol; 2018 Jul; 14(16):1531-1545. PubMed ID: 29411654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine.
    Cortes J; Vahdat L; Blum JL; Twelves C; Campone M; Roché H; Bachelot T; Awada A; Paridaens R; Goncalves A; Shuster DE; Wanders J; Fang F; Gurnani R; Richmond E; Cole PE; Ashworth S; Allison MA
    J Clin Oncol; 2010 Sep; 28(25):3922-8. PubMed ID: 20679609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.
    Vahdat LT; Pruitt B; Fabian CJ; Rivera RR; Smith DA; Tan-Chiu E; Wright J; Tan AR; Dacosta NA; Chuang E; Smith J; O'Shaughnessy J; Shuster DE; Meneses NL; Chandrawansa K; Fang F; Cole PE; Ashworth S; Blum JL
    J Clin Oncol; 2009 Jun; 27(18):2954-61. PubMed ID: 19349550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eribulin: a novel cytotoxic chemotherapy agent.
    Preston JN; Trivedi MV
    Ann Pharmacother; 2012 Jun; 46(6):802-11. PubMed ID: 22619477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eribulin in Cancer Treatment.
    Swami U; Shah U; Goel S
    Mar Drugs; 2015 Aug; 13(8):5016-58. PubMed ID: 26262627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eribulin mesylate (Halaven) for breast cancer.
    Med Lett Drugs Ther; 2011 Apr; 53(1362):30-1. PubMed ID: 21502935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in therapy: eribulin improves survival for metastatic breast cancer.
    Morris PG
    Anticancer Drugs; 2010 Nov; 21(10):885-9. PubMed ID: 20838209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eribulin mesylate in breast cancer.
    Verdaguer H; Morilla I; Urruticoechea A
    Womens Health (Lond); 2013 Nov; 9(6):517-26. PubMed ID: 24161305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eribulin.
    Perry CM
    Drugs; 2011 Jul; 71(10):1321-31. PubMed ID: 21770478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.